We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Actavis’ Atypical Antipsychotic Saphris for Bipolar Kids
FDA Approves Actavis’ Atypical Antipsychotic Saphris for Bipolar Kids
The FDA approved an under-the-tongue formulation of Actavis’ atypical antipsychotic Saphris for 10- to 17-year-old children with bipolar 1 disorder. The company plans to begin marketing the new formulation in the second quarter.